Formulation Development
ON-BODY DELIVERY SYSTEMS - Analysis & Simulation of Injection Volume Accuracy
Christian Riva, MS, presents a case study proving it is possible to have a realistic prediction of the injection volume accuracy of a drug delivery system, even in an early stage of product development, when only a high-level product architecture is available.
EXECUTIVE INTERVIEW - Cambrex: Providing Big Value in the Small Molecule Outsourcing Market
Simon Edwards, President, CDMO Sales & Marketing at Cambrex, discusses the biggest trends in the small molecule outsourcing market.
DATA ANALYTICS - Leveraging Cloud-Based Data & Analytics to Optimize Pharmaceutical Manufacturing
Benzi Mathew explains how recognition is increasing about the powerful impact data and analytics can have on optimizing the manufacturing process and ensuring demand is met every time, all the time.
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH
Entera Bio Ltd. recently announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its…
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin
Dance Biopharm Holdings, Inc., recently presented data from its Phase 2 clinical study of Dance 501, a novel gentle mist formulation of human insulin administered with its….
Immutep to Receive Milestone Payment From GSK
Immutep Limited recently announced it will receive a milestone payment from GSK of $5.02 million related to the first patient being dosed in…..
Atlas Nanotech Announces Successful Development of First-Ever OTC Nanotechnology Vitamin A
Costas Inc. DBA Atlas Nanotech adds another unique nanotechnology medical product to its portfolio. Recently, CEO Dr. Julio Riestra announced the completion of development of…
Mustang Bio Announces Phase 1 Clinical Trial
Mustang Bio, Inc. recently announced that City of Hope, a world-renowned independent cancer research and treatment center, has opened and is beginning to treat its…
Novo Nordisk & Emisphere Announce Development Update
Novo Nordisk recently announced the Federal Food and Drug Administration (FDA) has approved Rybelsus, a semaglutide tablet, for the treatment of adults with type 2…
Minerva Neurosciences & Catalent Enter Commercial Supply Agreement
Minerva Neurosciences, Inc. and Catalent recently announced they have entered into a long-term commercial supply agreement for Roluperidone (MIN-101), an investigational compound under development by…
Aptevo Therapeutics Introduces New Adaptir Bispecific Antibody Candidate
Aptevo Therapeutics Inc. recently introduced a new immuno-oncology candidate, APVO603, built on Aptevo’s proprietary ADAPTIR bispecific antibody platform. Jane Gross, PhD, Chief Scientific Officer for…
Novel Small Molecule Drug Discovery Platform Harnesses Immune System to Defeat Cancers, Viral Infections & Inflammatory Diseases
Now, the power of nucleic acid technology is being harnessed to design small molecule nucleic acid hybrid (SMNH) drugs that harness the patient’s own immune system to defeat…..
Rafael Pharmaceuticals Announces Expansion Into France of Pivotal Phase 3 Trial
Rafael Pharmaceuticals, Inc. recently announced the expansion of its Phase 3 clinical trial for patients with metastatic pancreatic cancer (AVENGER 500) into France. AVENGER 500…
Wave Life Sciences Announces Fast Track Designation from US FDA
Wave Life Sciences Ltd. recently announced the US FDA has granted Fast Track designation to suvodirsen for the treatment of Duchenne muscular dystrophy (DMD) in…
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 Trial
Ovid Therapeutics Inc. recently announced the first patient has been randomized in the company’s single, pivotal Phase 3 NEPTUNE clinical trial evaluating OV101 (gaboxadol), a…
Cellectar Presents Data From Phase 1 Study
Cellectar Biosciences, Inc. recently announced Mr. Jarrod Longcor, chief business officer of Cellectar presented data from Cohort 6 of its Phase 1 dose escalation study…
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial
Allena Pharmaceuticals, Inc. recently announced it has completed enrollment in its pivotal Phase 3 URIROX-1 clinical trial. URIROX-1 is a multi-center, global, randomized, double-blind, placebo-controlled…
Oramed Announces Last Patient Treated in Pivotal Oral Insulin Trial
Oramed Pharmaceuticals Inc. recently announced the treatment of the last patient in the primary cohort of the Phase 2b HbA1c trial evaluating Oramed's lead oral…
TYME Presents Positive Circulating Tumor Cell Data
Tyme Technologies, Inc. recently reported encouraging data on circulating tumor cells (CTCs) and a correlation with decrease in risk of death using TYME's lead candidate,…
Kitov Pharma Presents Newly Released Data for Reversing Pancreatic Cancer Drug Resistance
Kitov Pharma Ltd. recently presented newly released proof-of-concept data showing evidence of NT-219 mechanism of action in reversing cancer drug resistance in PDX models. The…
